MARIA TEREZA NIETO CORONEL

Dr. MARIA TEREZA NIETO CORONEL

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
GMGabriela Angelica Martínez-Nava
Gabriela Angelica Martínez-Nava
LULaura Keren Urbina-Jara
Laura Keren Urbina-Jara
SASaul Lira Albarran
Saul Lira Albarran
HGHenry Leonidas Gomez
Henry Leonidas Gomez
Erika Ruiz-GarciaErika Ruiz-Garcia
Erika Ruiz-Garcia
MCMarlid Cruz-Ramos
Marlid Cruz-Ramos
(1) Background: Somatic mutations may be connected to the exposome, potentially playing a role in breast cancer’s development and clinical outcomes. There needs to be information regarding Latin American women specifically, as they are underrepresented in clinical trials and have limited access to somatic analysis in their countries. This study aims to systematically investigate somatic mutations in breast cancer patients from Latin America to gain a better understanding of tumor biology in the region. (2) Methods: We realize a systematic review of studies on breast cancer in 21 Latin American countries using various databases such as PubMed, Google Scholar, Web of Science, RedAlyc, Dianlet, and Biblioteca Virtual en Salud. Of 392 articles that fit the criteria, 10 studies have clinical data which can be used to create a database containing clinical and genetic information. We compared mutation frequencies across different breast cancer subtypes using statistical analyses and meta-analyses of proportions. Furthermore, we identified overexpressed biological processes and canonical pathways through functional enrichment analysis. (3) Results: 342 mutations were found in six Latin American countries, with the TP53 and PIK3CA genes being the most studied mutations. The most common PIK3CA mutation was H1047R. Functional analysis provided insights into tumor biology and potential therapies. (4) Conclusion: evaluating specific somatic mutations in the Latin American population is crucial for understanding tumor biology and determining appropriate treatment options. Combining targeted therapies may improve clinical outcomes in breast cancer. Moreover, implementing healthy lifestyle strategies in Latin America could enhance therapy effectiveness and clinical outcomes.

1 January 2024 in International Journal of Breast Cancer
Verified
Journal Article
Open access
MCMARIA TEREZA NIETO CORONEL
MARIA TEREZA NIETO CORONEL
AOAlette Ortega
Alette Ortega
RYR. Yacab
R. Yacab
Edith Araceli Fernández-FigueroaEdith Araceli Fernández-Figueroa
Edith Araceli Fernández-Figueroa
César López-CamarilloCésar López-Camarillo
César López-Camarillo
Erika Ruiz-GarciaErika Ruiz-Garcia
Erika Ruiz-Garcia
Background: Trastuzumab resistance is associated with overexpressing the human epidermal growth factor receptor 2 (HER‐2), which results from the altered phosphoinositide 3‐kinase (PI3K) pathway in breast cancer patients.Objective: We quantified the frequency of PI3K enzyme single and double‐point mutations in Mexican patients with HER‐2 overexpressing breast cancer and its association with clinical‐pathological variables.Methods: We embedded HER‐2 breast samples in paraffin from 60 patients, extracted their DNA, and evaluated PI3K mutations in 49 HER‐2‐positive breast tumors. We focused on mutations for one exon 20 (H1047R) and two exon 9 PI3K (E545K, E542K) hotspots and characterized them as single and double‐point mutations. The mean patient follow‐up was 86 months.Results: Of 49 patients who tested positive for HER‐2 breast cancer, 14.28% showed mutations in PI3K, 71.42% single‐point, and 28.56% double‐point mutations. We found single‐point mutations in H1047R (42.85%) and E545K (28.57%). Only two patients exhibited double‐point mutations: one in E542K/E545K and another in H1047R/E545K (14.28% each). Although we observed lower survival in patients with mutations in PI3K, we did not find a significant association between these factors (p = 0.191). However, single and double‐point mutations in PI3K were significantly associated with the clinical stages of diagnosis and tumor size (p = 0.027 and p = 0.04, respectively).Conclusion: Single and double‐point mutations in PI3K are related to tumor size and advanced clinical–pathological traits in Mexican patients with HER‐2 overexpression, and future molecular studies are necessary to understand these findings.

30 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
KSKristian Shtembari
Kristian Shtembari
MCMartina Catalano
Martina Catalano
IVIsmaela Anna Vascotto
Ismaela Anna Vascotto
CCChiara Calandrelli
Chiara Calandrelli
SMSilvia Mancini
Silvia Mancini
giandomenico roviellogiandomenico roviello
giandomenico roviello
Immune checkpoint inhibitor-related pneumonitis (CIP) is an uncommon but clinically relevant toxicity in renal cell carcinoma (RCC), where immune checkpoint inhibitors are frequently used either as dual immunotherapy or in combination with VEGF-targeted tyrosine kinase inhibitors. In RCC, CIP poses specific diagnostic challenges because respiratory symptoms and computed tomography findings may overlap with pulmonary metastases, infections, thromboembolic events, heart failure, and TKI-related lung toxicity. This review summarizes the incidence of CIP across pivotal RCC trials and real-world cohorts, compares its epidemiology with non-small cell lung cancer, and discusses clinical presentation, radiological patterns, differential diagnosis, and current management strategies. Particular attention is given to RCC-specific mechanisms, including immune-mediated alveolar injury, T cell activation, cytokine dysregulation, macrophage activation, GSDME-mediated pyroptosis, and the potential contribution of VEGF pathway inhibition to pulmonary inflammation. We also review risk factors, steroid-refractory disease, second-line immunosuppression, and the unresolved issue of ICI rechallenge after pneumonitis. A better understanding of these mechanisms and clinical features may improve early recognition, guide multidisciplinary management, and support safer use of immunotherapy-based combinations in patients with RCC.

6 October 2026 in The Oncologist
Verified
Journal Article
Open access
YÜYüksel Ürün
Yüksel Ürün
KSKannan Sridharan
Kannan Sridharan
ZAZgura Anca
Zgura Anca
AZAnas Zayed
Anas Zayed
MLMartin Ignacio Zapata Laguado
Martin Ignacio Zapata Laguado
MSMatteo Santoni
Matteo Santoni
Background: Renal Cell Carcinoma (RCC) represents a growing global health burden, with rising incidence and mortality worldwide. Despite major therapeutic advances, access to novel systemic treatments remains uneven across countries and regions. Methods: We conducted a cross-sectional, web-based international survey to assess the availability and reimbursement status of 20 innovative systemic therapies for RCC. Responses were collected from 144 clinicians, including medical oncologists, radiation oncologists, urologists, and nuclear medicine specialists, across 58 countries. Analyses examined associations between national income level, gross domestic product (GDP), and treatment availability. Findings: Thirty-six percent of the countries analyzed had at least 15 of the 20 therapies available. Full reimbursement for at least 15 of the selected innovative therapies was reported in six countries (10%), while 21 countries (36%) fully reimbursed 10-14 therapies and 13 countries (23%) reimbursed 1-9 therapies. In contrast, no full reimbursement for any of the assessed therapies was reported in 18 countries (31%). Higher national income level was significantly associated with greater availability of innovative therapies (Kruskal–Wallis test, P < .0001). Armenia (0.709), Greece (0.685), and Israel (0.666) exhibited the highest GDP-adjusted Drug Availability Index (DAI), whereas India (5.195), Nigeria (4.612), and Morocco (3.794) demonstrated the greatest number of available therapies per US$1000 of GDP per capita. Interpretation: Access to innovative systemic therapies for RCC remains highly unequal at the global level, with reimbursement posing a major barrier even where drugs are available. Internationally coordinated efforts addressing health policy, infrastructure, and equitable pricing are urgently required to ensure that advances in RCC treatment translate into improved outcomes for patients across diverse economic settings.

27 July 2026
Verified
Book
Open access
MRMauricio Alejandro Paz del Rio
Mauricio Alejandro Paz del Rio
MMMicaela Mariel Moncada Mercado
Micaela Mariel Moncada Mercado
FBFreddy Ednildon Bautista-Vanegas
Freddy Ednildon Bautista-Vanegas
LGLuis Mariano Tecuatl Gómez
Luis Mariano Tecuatl Gómez
JTJaykel Evelio Gómez Triana
Jaykel Evelio Gómez Triana
IGIsmael Vargas Gallego
Ismael Vargas Gallego
The rapid expansion of biomedical literature has increased the need for healthcare professionals to critically evaluate scientific evidence before incorporating it into clinical practice. This book presents a comprehensi

11 March 2026 in Ethics, Medicine and Public Health
Verified
Journal Article
Closed access
MCMARIA TEREZA NIETO CORONEL
MARIA TEREZA NIETO CORONEL
DGD. Shveid Gerson
D. Shveid Gerson